| Total income for the quarter was marginally lower at Rs 323.34 crore as compared to Rs 325.39 crore for the corresponding period last year. On a sequential basis, the total income for the third quarter was higher by 19 per cent and the net profit was up by a whopping 313.68 per cent. |
| During the quarter, higher interest costs at Rs 10.42 crore (Rs 7.81 crore) and depreciation Rs 12.58 crore (Rs 9.09 crore) were absorbed. These higher expenses were on account of investments in research and development and production infrastructure for regulatory markets. |
| The company has also written off R&D expenditure of Rs 10.37 crore (Rs 8.14 crore) during the quarter. |
| The company has also accelerated the DMF/ANDA filings programme and the third quarter witnessed 11 DMFs filings (cumulative 64) and five ANDA /formulation dossier filings (cumulative 15) in the US and European Union. |
| In the US, the company has filed seven DMFs (cumulative 22) and five ANDAs (cumulative 11) in Q3. |
| During the quarter, another major milestone has been crossed in its foray into the regulated markets with the successful inspection of the audit of the manufacturing facility by the USFDA. |
| The company has also received USFDA approval for its ANDA for metformin. Metformin is indicated in the treatment of diabetes. This is the third product approval that the company has received from the USFDA for marketing in the US. The product is one among the top 10 products in terms of volumes in the US. |
| Downslide |
|
Top Section
Explore Business Standard